Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome

Circulation

Volumn 105, Issue 13, 2002, Pages 1555-1560

  Sinisalo, Juha ^a   Mattila, Kimmo ^a   Valtonen, Ville ^a   Anttonen, Olli ^b   Juvonen, Jukka ^c   Melin, John ^d   Vuorinen Markkola, Helena ^a   Nieminen, Markku S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Lahti Central Hospital   (Finland)

^c Kajaani Central Hospital   (Finland)

^d JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

Angina; Coronary disease; Infection

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; UNSTABLE ANGINA PECTORIS;

ADOLESCENT; ADULT; AGED; ANGINA, UNSTABLE; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SURVIVAL RATE; SYNDROME; TIME FACTORS;

EID: 0037007128     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000012544.07696.1F     Document Type: Article

References (21)

1. Acute coronary syndromes: Biology
2. Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research
3. Role of infection as a risk factor for atherosclerosis, myocardial infarction and stroke
4. Serological evidence of an association of a novel Chlamydia TWAR, with chronic heart disease and acute myocardial infarction
5. Prospective study of pathogen burden and risk of myocardial infarction or death
6. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction
7. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study
8. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary clinical results of the ACADEMIC study
9. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): A randomised, doubleblind, placebo-controlled trial
10. Mechanisms of disease: Atherosclerosis - An inflammatory disease
11. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: The final report of the ROXIS study
12. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
13. Low-molecular-weight heparin during instability in coronary artery disease
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
15. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at post-mortem examination and histological severity (Stary grading) of associated atherosclerotic plaque
16. Mouse models of C. pneumoniae infection and atherosclerosis
17. Acute respiratory-tract infections and risk of first-time acute myocardial infarction
18. Dental infections as a risk factor for acute myocardial infarction
19. Anti-inflammatory activity of macrolides: A new therapeutic potential?
20. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study